Description
Repaglinide is a derivative of meglitinide that non-selectively binds the sulfonylurea subunit of ATP-sensitive K+ channels, inducing channel closure. Repaglinide is a fast acting anti-diabetic compound that increases insulin release.
Repaglinide
Product ID R1860
Cas No. 135062-02-1
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 135062-02-1 |
|---|---|
| Purity | ≥98% |
| Formula | C27H36N2O4 |
| Formula Wt. | 452.59 |
| Chemical Name | 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid |
| IUPAC Name | 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2- oxoethyl]benzoic acid |
| Melting Point | 130-131°C |
| Appearance | White to off white powder |
Shipping and Storage
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Zünkler BJ. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacol Ther. 2006 Oct;112(1):12-37. PMID: 16647758.
Proks P, Reimann F, Green N, et al. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. PMID: 12475777.
Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41(7):471-83. PMID: 12083976.